Healthy adult
Conditions
Interventions
Consume one bottle (50 mL) of test drink 5 min before the load food intake. Rest more than 5 days. Consume one bottle (50 mL) of control drink 5 min before the load food intake.
Consume one bottle (50
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Male and Females aged 20 to 64 when informed consent. 2) Subjects their fasting blood glucose are between 110 and 125 mg/dL or their blood glucose level of 120 min after OGTT are between 140 and 199 mg/dL. 3) Subjects who receive enough explain of the test, who deeply understanding of the test, and who obtain own consent to participate the test.
Exclusion criteria
Exclusion criteria: 1) Subjects who are being received treatment and/or medication when informed consent. 2) Subjects who are not able to quit intake medicine, food for specific health, functional food and/or supplement having a possibility of affecting blood glucose level during test period. 3) Females who are pregnant or lactating, and females who could become pregnant or lactating during test period. 4) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ). 5) Subjects who excessive alcohol intake. 6) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work. 7) Subjects who excessive alcohol intake. 8) Subjects who have weak digestive organ and/or have tendency of diarrhea. 9) Subjects who show more than 6.5 % in HbA1c level at preliminary test. 10) Subjects who show more than 160 mg/dL in fasting blood glucose level measured by glucose sensor at preliminary test. 11) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. 12) Subjects who donated over 200 mL blood and/or blood components within the last one month to the current study. 13) Subjects who donated over 400mL blood and/or blood components within the last three months to the current study. 14) Females who donated over 400mL blood and/or blood components within the last four months to the current study. 15) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study. 16) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study. 17) Others they have been determined ineligible by principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| *Area under the concentration time curve of blood glucose *Area under the concentration time curve of blood insulin | — |
Secondary
| Measure | Time frame |
|---|---|
| *Area under the concentration time curve of blood triglyceride *Blood glucose level of each measuring point *Blood insulin level of each measuring point *Blood triglyceride level of each measuring point *Cmax of blood glucose level *Tmax of blood glucose level *Cmax of blood insulin level *Tmax of blood insulin level *Cmax of blood triglyceride level *Tmax of blood triglyceride level *The incidence of side effects and/or adverse events | — |
Countries
Japan
Contacts
Public ContactMasanori Numa
CPCC Company Limited Planning & Sales Department
Outcome results
None listed